Natarajan Sethuraman Sells 25,907 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 25,907 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider directly owned 216,317 shares of the company’s stock, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Trading Down 0.3%

TRDA stock opened at $15.75 on Wednesday. The stock has a 50-day moving average price of $12.81 and a 200-day moving average price of $10.82. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $16.19. The firm has a market cap of $611.42 million, a PE ratio of -4.55 and a beta of -0.09.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.38. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. On average, analysts forecast that Entrada Therapeutics, Inc. will post -4.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TRDA has been the topic of a number of research analyst reports. Cantor Fitzgerald initiated coverage on Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating on the stock. Oppenheimer boosted their target price on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, April 6th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its holdings in Entrada Therapeutics by 9.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after acquiring an additional 1,560 shares during the period. Alliancebernstein L.P. raised its holdings in Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after acquiring an additional 1,620 shares during the period. Great Lakes Advisors LLC increased its holdings in shares of Entrada Therapeutics by 5.5% in the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after purchasing an additional 2,239 shares during the period. Quadrature Capital Ltd increased its holdings in shares of Entrada Therapeutics by 13.5% in the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after purchasing an additional 2,424 shares during the period. Finally, First Trust Advisors LP increased its holdings in shares of Entrada Therapeutics by 3.6% in the second quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after purchasing an additional 2,631 shares during the period. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.